IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy

Cytokines were the first modern immunotherapies to produce durable responses in advanced cancer, but their application has been hampered by modest efficacy and limited tolerability(1,2). In an effort to identify alternative cytokine pathways for immunotherapy, we found that components of the Interle...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Ting, Damsky, William, Weizman, Orr-El, McGeary, Meaghan K., Hartmann, K. Patricia, Rosen, Connor E., Fischer, Suzanne, Jackson, Ruaidhri, Flavell, Richard A., Wang, Jun, Sanmamed, Miguel F., Bosenberg, Marcus W., Ring, Aaron M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381364/
https://www.ncbi.nlm.nih.gov/pubmed/32581358
http://dx.doi.org/10.1038/s41586-020-2422-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381364/
https://www.ncbi.nlm.nih.gov/pubmed/32581358
http://dx.doi.org/10.1038/s41586-020-2422-6

Ejemplares similares